EVFM insider filings
Evofem Biosciences, Inc. — 47 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-01-12. Screen EVFM transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for EVFM between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Evofem Biosciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-01-12 | 4 | Zhang Yan — CFO | Sale (S): 104 @ $0.04 | EDGAR |
| 2023-12-22 | 4 | Kamdar Kim P. — Director | Sale (S): 10 @ $0.62 | EDGAR |
| 2023-04-26 | 4 | PELLETIER SAUNDRA L — Chief Executive Officer, Director | Disposition to issuer (D): 50,000 @ $0 | EDGAR |
| 2022-05-31 | 4 | PELLETIER SAUNDRA L — Chief Executive Officer, Director | Purchase (P): 141,000 @ $0.35 | EDGAR |
| 2022-05-06 | 4 | O'Brien Anthony Stephen — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-05-06 | 4 | Rutherford Colin — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-05-06 | 4 | Rarick Lisa Dale — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-05-06 | 4 | Greer Gillian — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-05-06 | 4 | Kamdar Kim P. — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-02-23 | 4 | File Justin J. — Chief Financial Officer | Grant/award (A): 450,000 @ $0 · Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2022-02-23 | 4 | Fitzpatrick Alexander A — General Counsel and Secretary | Grant/award (A): 300,000 @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2022-02-23 | 4 | PELLETIER SAUNDRA L — Chief Executive Officer, Director | Grant/award (A): 750,000 @ $0 · Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2022-01-04 | 4 | File Justin J. — Chief Financial Officer | Disposition to issuer (D): 120,000 @ $0 | EDGAR |
| 2022-01-04 | 4 | Fitzpatrick Alexander A — General Counsel and Secretary | Disposition to issuer (D): 120,000 @ $0 | EDGAR |
| 2022-01-04 | 4 | PELLETIER SAUNDRA L — Chief Executive Officer, Director | Disposition to issuer (D): 300,000 @ $0 | EDGAR |
| 2021-12-20 | 4 | File Justin J. — Chief Financial Officer | Purchase (P): 40,594 @ $0.37 | EDGAR |
| 2021-12-20 | 4 | Fitzpatrick Alexander A — General Counsel and Secretary | Purchase (P): 25,000 @ $0.39 | EDGAR |
| 2021-12-20 | 4 | PELLETIER SAUNDRA L — Chief Executive Officer, Director | Purchase (P): 135,000 @ $0.38 | EDGAR |
| 2021-07-09 | 4 | Barrans Russell — Chief Commercial Officer | Tax withholding (F): 19,998 @ $0.97 | EDGAR |
| 2021-06-21 | 4 | Kamdar Kim P. — Director | Purchase (P): 10,000 @ $1.17 | EDGAR |
| 2021-06-14 | 4 | Rarick Lisa Dale — Director | Purchase (P): 5,000 @ $1.20 | EDGAR |
| 2021-06-14 | 4 | O'Brien Anthony Stephen — Director | Purchase (P): 8,140 @ $1.31 | EDGAR |
| 2021-06-11 | 4 | Barrans Russell — Chief Commercial Officer | Purchase (P): 18,180 @ $1.14 | EDGAR |
| 2021-06-10 | 4 | File Justin J. — Chief Financial Officer | Purchase (P): 24,500 @ $1.03 | EDGAR |
| 2021-06-10 | 4 | Fitzpatrick Alexander A — General Counsel and Secretary | Purchase (P): 10,000 @ $1.02 | EDGAR |
| 2021-06-10 | 4 | PELLETIER SAUNDRA L — Chief Executive Officer, Director | Purchase (P): 50,000 @ $1.03 | EDGAR |
| 2021-05-21 | 4 | Barrans Russell — Chief Commercial Officer | Tax withholding (F): 31,480 @ $0.86 | EDGAR |
| 2021-05-21 | 4 | Culwell Kelly — Chief Medical Officer | Tax withholding (F): 42,061 @ $0.86 | EDGAR |
| 2021-05-21 | 4 | File Justin J. — Chief Financial Officer | Tax withholding (F): 42,280 @ $0.86 | EDGAR |
| 2021-05-21 | 4 | Fitzpatrick Alexander A — General Counsel and Secretary | Tax withholding (F): 42,120 @ $0.86 | EDGAR |
| 2021-05-21 | 4 | PELLETIER SAUNDRA L — Chief Executive Officer, Director | Tax withholding (F): 105,300 @ $0.86 | EDGAR |
| 2021-05-13 | 4 | Greer Gillian — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Rutherford Colin — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Rarick Lisa Dale — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | O'Brien Anthony Stephen — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Hall William Walmsley — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Kamdar Kim P. — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2021-03-09 | 4 | PELLETIER SAUNDRA L — Chief Executive Officer, Director | Purchase (P): 45,249 @ $2.28 | EDGAR |
| 2021-02-03 | 4 | Barrans Russell — Chief Commercial Officer | Grant/award (A): 200,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | File Justin J. — Chief Financial Officer | Grant/award (A): 200,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Culwell Kelly — Chief Medical Officer | Grant/award (A): 200,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Fitzpatrick Alexander A — General Counsel and Secretary | Grant/award (A): 200,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | PELLETIER SAUNDRA L — Chief Executive Officer, Director | Grant/award (A): 500,000 @ $0 · Grant/award (A): 700,000 (derivative) @ $0 | EDGAR |
| 2020-11-18 | 4 | File Justin J. — Chief Financial Officer | Purchase (P): 7,760 @ $2.17 | EDGAR |
| 2020-11-18 | 4 | Fitzpatrick Alexander A — General Counsel and Secretary | Purchase (P): 9,090 @ $2.20 | EDGAR |
| 2020-09-11 | 4 | Barrans Russell — Chief Commercial Officer | Purchase (P): 1,000 @ $2.71 · Purchase (P): 3,000 @ $2.08 | EDGAR |
| 2020-09-10 | 4 | PELLETIER SAUNDRA L — Chief Executive Officer, Director | Sale (S): 122,500 @ $3.26 | EDGAR |
Recent 8-K events — Evofem Biosciences, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-18 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EVFM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs